Biallelic mutations in neurofascin cause neurodevelopmental impairment and peripheral demyelination

Stephanie Efthymiou,1,2 Vincenzo Salpietro,1,2 Nancy Malintan,2 Mallory Poncelet,3 Yamma Kriouile,4 Sara Fortuna,5 Rita De Zorzi,5 Katelyn Payne,6 Lindsay B. Henderson,7 Andrea Cortese,1 Sateesh Maddirevula,8 Nadia Alhashmi,9 Sarah Wiethoff,1,10 Mina Ryten,11 Juan A. Botia,11,12 Vincenzo Provitera,13 Markus Schuelke,14 Jana Vandrovcová,1 SYNAPS Study Group,1,2,† Laurence Walsh,6 Erin Torti,7 Valeria Iodice,15,16 Maryam Najafi,17 Ehsan Ghayoor Karimiani,18 Reza Maroofian,18 Karine Siquier-Pernet,19,20 Nathalie Bodaert,19,21 Pascale De Lonlay,19,22 Vincent Cantagrel,19,20 Mhammed Aguennouz,23 Mohamed El Khorassani,4 Miriam Schmidts,17,24 Fowzan S. Alkuraya,25 Simon Edvardson,26,* Maria Nolano,13,27,* Jérôme Devaux3,3 and Henry Houlden1,*

*These authors contributed equally to this work.
†Appendix 1.

Axon pathfinding and synapse formation are essential processes for nervous system development and function. The assembly of myelinated fibres and nodes of Ranvier is mediated by a number of cell adhesion molecules of the immunoglobulin superfamily including neurofascin, encoded by the NFASC gene, and its alternative isoforms Nfasc186 and Nfasc140 (located in the axonal membrane at the node of Ranvier) and Nfasc155 (a glial component of the paranodal axoglial junction). We identified 10 individuals from six unrelated families, exhibiting a neurodevelopmental disorder characterized with a spectrum of central (intellectual disability, developmental delay, motor impairment, speech difficulties) and peripheral (early onset demyelinating neuropathy) neurological involvement, who were found by exome or genome sequencing to carry one frameshift and four different homozygous non-synonymous variants in NFASC. Expression studies using immunostaining-based techniques identified absent expression of the Nfasc155 isoform as a consequence of the frameshift variant and a significant reduction of expression was also observed in association with two non-synonymous variants affecting the fibronectin type III domain. Cell aggregation studies revealed a severely impaired Nfasc155-CNTN1/CASPR1 complex interaction as a result of the identified variants. Immunofluorescence staining of myelinated fibres from two affected individuals showed a severe loss of myelinated fibres and abnormalities in the paranodal junction morphology. Our results establish that recessive variants affecting the Nfasc155 isoform can affect the formation of paranodal axoglial junctions at the nodes of Ranvier. The genetic disease caused by biallelic NFASC variants includes neurodevelopmental impairment and a spectrum of central and peripheral demyelination as part of its core clinical phenotype. Our findings support possible overlapping molecular mechanisms of paranodal damage at peripheral nerves in both the immune-mediated and the genetic disease, but the observation of prominent central neurological involvement in NFASC biallelic variant carriers highlights the importance of this gene in human brain development and function.

Received February 7, 2019. Revised May 19, 2019. Accepted June 18, 2019

© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

In the vertebrate nervous system, myelinated fibres allow rapid nerve impulse transmission because of the ensheathment of their axons by specialized glial cells to form the multilamellar myelin sheath. Also, voltage-gated sodium channels (\(\text{Na}^+\)) are clustered at the nodes of Ranvier further facilitating the rapid conduction of nerve impulses.
impulses in the vertebrate brain and peripheral nerves (Ghosh et al., 2018). Neurofascin protein isoforms Nfasc186 and Nfasc155 are splice variants encoded by the NFASC gene (MIM: 609145) and belong to the L1 family of immunoglobulin cell adhesion molecules, which play a critical role in the assembly of the node of Ranvier (Ghosh et al., 2018). Nfasc155 is a glial isoform abundantly expressed in myelinating Schwann cells and predominantly enriched at the paranodal sites, acting as a ligand for the axonal contactin-1 (CNTN1)/contactin-associated protein-1 (CASPR1) complex. Nfasc186 represents the axonal isoform expressed at the node of Ranvier membranes where it is involved in the long-term maintenance and stability of Na+ channels (Fig. 1) (Sherman et al., 2005; Taylor et al., 2018).

Autoantibodies against Nfasc186 and Nfasc155 are associated with severe forms of chronic inflammatory demyelinating polyneuropathy (CIDP) and cause an immune-mediated nodo-paranodopathy (Querol et al., 2017; Vallat et al., 2018) further demonstrating that these proteins play a crucial role in conduction. Biallelic variants in gliomedin (GLDN) and CNTNAP1 encoding essential components of the nodes of Ranvier and paranodes, respectively, lead to inherited nodo-paranodopathies, a distinct disease entity among peripheral neuropathies (Maluenda et al., 2016). Smigiel et al. (2018) report the identification of a homozygous truncating NFASC mutation affecting the fibronectin type III domain, specific to the Nfasc155 isoform in a child presenting with a very severe neurodevelopmental disorder resembling spinal muscular atrophy, while Monfrini et al. (2019) report a homozygous missense mutation in a case with autosomal recessive ataxia and a demyelinating neuropathy. Importantly, a human Mendelian disease caused by NFASC variants has been reported only in these two single individuals to date.

Here, we describe 10 individuals from six families carrying homozygous non-synonymous or frameshift variants in NFASC. Phenotypic analysis of affected individuals revealed, in all cases, global developmental delay and weakness with variable features of chronic demyelinating neuropathy in some cases. For some of the identified variants, we compared surface expression of the disease variant and wild-type Nfasc155 isoforms. We also tested the capability of variant proteins to interact with other partner proteins at paranodal sites, including gliomedin and the CNTN1/CASPR1 complex. Abnormalities of paranodal junction were identified by immunofluorescence analyses of myelinated fibres from skin samples of two affected individuals carrying homozygous variants in NFASC. Our results link biallelic variants in NFASC isoforms at glial cells to defects in the paranodal axoglial junctions and phenotypes that range from variable neurodevelopmental impairment to weakness, central hypomyelination, and peripheral chronic demyelinating neuropathy.

Materials and methods

This study was approved by local institutional IRB/ethical review boards of all participating centres, and written informed consent was obtained prior to genetic testing from all the families involved. Clinical details were obtained through medical file review and clinical examination. Genomic DNA was extracted from peripheral blood samples according to standard procedures. Whole exome sequencing (WES) was performed as described elsewhere (Mencacci et al., 2016), and our bioinformatics filtering strategy included screening for only exonic and donor/acceptor splicing variants. In accordance with the pedigree and phenotype, priority was given to rare variants [<0.01% in public databases, including 1000 Genomes project, NHLBI Exome Variant Server, Complete Genomics 69, and Exome Aggregation Consortium (ExAC v0.2)] that were fitting a recessive (homozygous or compound heterozygous) or a de novo model and/or variants in genes previously linked to neuropathy, intellectual disability and other neurological disorders. Other families were recruited through GeneMatcher (https://genematcher.org).

Molecular biology

NFASC missense constructs were cDNA synthesized by GenScript into pCMV-3Tag-4A by replacing the coding sequence for these inserts via BamHI and XhoI (NEB), giving rise to pCMV_Nfasc186 [WT], pCMV_Nfasc186 [N130D], pCMV_Nfasc186 [R395P], pCMV_Nfasc186 [P694T], pCMV_Nfasc186 [S820P], pCMV_Nfasc155 [WT], pCMV_Nfasc155 [N124D], pCMV_Nfasc155 [R370P], pCMV_Nfasc155 [P705T], pCMV_Nfasc155 [S831P] and pCMV_Nfasc155 [P939Ter].

To generate pCMV_Nfasc155 [P939Ter], the respective variant was introduced with the QuickChange Site-Directed Mutagenesis Kit (Agilent Technologies). A Myc epitope was then inserted before the stop codon into pCMV_Nfasc155 [P939Ter] using site-directed mutagenesis kit with primers: 5’-GACACAAAATCTCATCCAGAGGAGTCTGgtgattggatacctcaa-3’ and 5’-CGAGATCCTTCCTTCTGAGATGAGTTTTGTTCTGATCCCATTITGGATGCTCAG-3’.

Cell assays

Human embryonic kidney (HEK) cells were transfected with Nfasc155 or Nfasc186 variants using JetPEI (Polyplus-transfection). After 48 h, cells were incubated for 20 min at 37°C with rabbit antibodies against Nfasc186 (DeG60; Cell Signaling Technology) or Nfasc155 (D7B6O; Cell Signaling Technology) diluted 1/50 in Opti-MEM™ or with 1 μg of gliomedin-Fc (Devaux, 2012) diluted in Opti-MEM™ (ThermoFisher Scientific). Cells were then washed in phosphate-buffered saline (PBS), fixed with 0.1% Triton X-100 in PBS. HEK cells were incubated with a mouse anti-Myc antibody (Roche; 1/200) for 1 h, then incubated with Alexa conjugated secondary antibodies (1/500; Jackson ImmunoResearch) for 30 min. Coverslips were washed three times in PBS, stained with DAPI, and mounted with Mowiol® plus 2% DABCO.
some experiments, HEK cells were co-transfected with GFP and Nfasc155 variants. In those experiments, cells were fixed and revealed with a mouse anti-Myc antibody. Immunostainings were examined using an ApoTome fluorescence microscope (ApoTome, AxioObserver and AxioCam MRm, Carl Zeiss MicroImaging GmbH). Digital images were manipulated into figures with CorelDRAW and Corel Photo-Paint.

**Figure 1** Schematic diagram showing the different domains of a myelinated axon. The axonal region around the node of Ranvier is expanded to show the different axonal domains: the node of Ranvier where voltage-gated Na⁺ channels (Nav1.6 and Nav1.1) are expressed, the paranode where the myelin is attached to the axon, and the juxtaparanode where most voltage-gated K⁺ channels (KCNQ2/3 and Kv1) are located. Each of these domains is characterized by the expression of specific cell adhesion molecules: at the nodes Nfasc186 binds gliomedin (GLDN) and NrCAM, which are secreted by Schwann cells in the nodal gap lumen, at the paranode Nfasc155 forms a complex with CNTN1/CASPR1 to form the septate-like junctions, and at the juxtaparanode the CNTN2/CASPR2 complex enables the sequestration of Kv1 channels. Adapted and modified from Arancibia-Carcamo and Attwell (2014).

### Cell aggregation assay

N2A cells were plated in 6-well plates at a density of 500,000 cells/well and were transiently transfected using JetPEI (Polyplus-transfection) with Nfasc155 and ptdTomato-N1 (Clontech), CNTN1/CASPR1 and peGFP-N1 (Clontech), or peGFP-N1 alone. The day after, cells were trypsinized using 0.05% trypsin in PBS and suspended in 1 ml serum
free Opti-MEM™ medium (ThermoFisher Scientific). Cells were mixed together in a 1:1 ratio (400 000 cells/ml), and then agitated at 100 rpm for 2 h at 37°C. Cell suspension (100 µl) was then mounted between slides and coverslip, and was immediately observed using a fluorescence microscope with 5× objective. The number of cells in mixed aggregates was evaluated in 10 fields. Aggregates were defined as clusters of at least four cells including red and green cells. The four experiments were performed for each condition.

**Immunoblots**

HEK cells were transfected with Nfasc155 constructs for 24 h, then the cells were washed in PBS and solubilized on ice for 15 min in 1% Triton™ X-100, 140 mM NaCl, 20 mM Tris-HCl, pH 7.4 containing protease inhibitors. Proteins (50 µg) were loaded on 7.5% SDS-PAGE gels, transferred, and immunoblotted with a mouse antibody against Myc (1:2000) or a mouse antibody against α-tubulin (1:2000; MABT205; Merck). Immunoreactivity was revealed using peroxidase-coupled secondary antibodies (1:5000; Jackson ImmunoResearch) and BM chemiluminescence kit (Roche). The integrated densities of each protein band were measured with ImageLab software (Bio-Rad).

**Molecular modelling**

Wild-type and mutated NFASC isoforms were built from structure PDB ID 3P3Y (Supplementary material). Each protein was placed in a cubic box and minimized. A water layer of 0.8 nm and Na⁺ ions to neutralize the system were added, and a second minimization was performed. In all cases we used AMBER99SB-ILDN (Lindorff-Larsen et al., 2010) force field and simple point charge water. In all systems we performed NVT [constant number of atoms, volume and temperature (canonical ensemble)] and NPT [constant number of atoms, pressure and temperature (isothermal-isobaric ensemble)] equilibrations for 100 ps, followed by 360 ns NPT production run at 300 K. The temperature was controlled with a modified Berendsen thermostat (Bussi et al., 2007), and the pressure with an isotropic Parrinello-Rahman, at 100 kPa. The iteration time step was set to 2 fs, with the Verlet integrator and LINCS (Hess, 2008) constraint. We used periodic boundary conditions. Configurations were sampled every 10 ps. All the simulations and their analyses were run as implemented in the GROMACS package (Pronk et al., 2013).

**Immunofluorescence staining of patient skin**

Skin samples (3 mm) were taken using a disposable punch after intradermal injection of lidocaine from the leg and forearm of Patient 1, and from leg, thigh and fingertip of Patient 3, and of a 5-year-old male with a suspected indifference to pain as control. Specimens were fixed overnight in Zamboni solution (American Mastertech), cryoprotected in 20% sucrose in PBS and sent in a refrigerated package to the laboratory of Telese. The skin samples were cut into 50-µm thick sections using a freezing slide microtome (Leica 2000R). Free-floating sections were processed for indirect immunofluorescence using antibodies to stain nerve fibres, myelin and vascular structures. To visualize nodal and paranodal architecture, rabbit antibodies against panNeurofascin (1:2000, courtesy of Prof P. Brophy), Nfasc186 (1:800, Cell Signaling Technology) or CASPR1 (1:1000, Abcam) were used. Axon and myelin were visualized with primary mouse antibodies against protein gene product 9.5 (PGP; AbD Serotec; 1:3000), myelin basic protein (MBP; Santa Cruz Biotechnology; 1:800), or collagen IV (COLIV; Chemicon; 1:800) or a rabbit antibody against PGP (Biogenesis; 1:400). Species-specific secondary antibodies coupled with cyanine 2 and cyanine 3 fluorophores were used to visualize the structures of interest. ULEX European agglutinin 1 coupled with cyanine 5 was used to visualize blood vessels and epidermis. Skin sections were mounted on coverslips with agar, dehydrated in alcohol, clarified in methyl-salicylate and finally mounted in DPX. Digital images were acquired using a non-laser confocal microscope (Apolome; Zeiss).

**Co-expression network analysis**

Co-expression network analysis was used to investigate the function of NFASC across the human central and peripheral nervous system. This analysis was performed by using GTEx V6 gene expression data (Carithers et al., 2015) to generate co-expression networks for each of the 13 brain tissues and tibial nerve RNA-seq data included within the GTEx study. The raw FPKM (fragments per kilobase of transcript per million mapped reads) values were corrected for known batch effects, age at death, sex and post-mortem interval, as well as unknown effects. The unknown effects were detected with the surrogate variable analysis (SVA) R Package (Leek and Storey, 2007) and correction was performed using ComBat (Johnson et al., 2007). The resulting residuals were used to create a signed network using the blockwiseConsensusModules R function from the WGCNA R package (Langfelder and Horvath, 2008) for each of the 14 tissues. Next, the modules obtained in each of the 14 networks were assigned to cell types using the userListEnrichment R function of the blockwiseConsensusModules R function from the WGCNA R package (Langfelder and Horvath, 2008) for each of the 14 tissues. Next, the modules obtained in each of the 14 networks were assigned to cell types using the userListEnrichment R function implemented in the WGCNA R package, which measures enrichment between module-assigned genes and defined brain-related lists using a hypergeometric test. The same approach was used to annotate modules with Gene Ontology, REACTOME (Fabregat et al., 2018) and KEGG (Kanehisa et al., 2016) terms.

**Data availability**

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

**Results**

**Identification of the NFASC variants**

Biallelic NFASC variants were independently identified as the primary candidate genetic cause for the phenotype observed in the six families described herein (Fig. 2 and Table 1). WES carried out in Family 1 (Fig. 2) revealed a homozygous variant in NFASC (chr1:204948591C>A). This variant
### Table 1  NFASC intragenic variants identified in our cohort

| Family | Genomic coordinates (GRCh37/hg19) | Variant | dbSNP | 1000G | ESP6500 | ExAC | gnomAD | SIFT | PolyPhen | Condel | CADD PHRED | GERP++ |
|--------|----------------------------------|---------|-------|-------|---------|------|--------|------|----------|--------|------------|--------|
| 1      | 1:204948591–204948591            | ENST00000339876.6 | -     | -     | -      | -    | -      | -    | Deleterious (0) | 25.4   | 5.24       |
|        | Nfasc 186c.2080C>A;p.P694T       |         |       |       |         |      |        |      | Deleterious (0.998) |
|        | Nfasc 155c.2113C>A;p.P705T       |         |       |       |         |      |        |      | Deleterious (0.919) |
| 2      | 1:204986105–204986106            | ENST000003403.5 | -     | -     | -      | -    | -      | -    | -        | -      | -          | -      |
|        | Nfasc 155c.2816delC:p.P929Ter    |         |       |       |         |      |        |      | -        | -      | -          | -      |
| 3      | 1:204923488–204923488            | ENST00000339876.6 | -     | -     | -      | -    | -      | -    | Tolerated (0.07) | 21.5   | 5.37       |
|        | Nfasc 186c.388A>G;p.N130D         |         |       |       |         |      |        |      | Possibly damaging (0.67) |
|        | Nfasc 155c.298A>G;p.N124D         |         |       |       |         |      |        |      | Deleterious (0.556) |
| 4      | 1:204951136–204951136            | ENST00000339876.6 | -     | -     | -      | -    | -      | -    | Deleterious (0) | 28.6   | 5.55       |
|        | Nfasc 186c.2458T>C;p.S820P        |         |       |       |         |      |        |      | Probably damaging (1) |
|        | Nfasc 155c.2491T>C;p.S831P        |         |       |       |         |      |        |      | Deleterious (0.945) |
| 5      | 1:204939816–204939816            | ENST00000339876.6 | -     | -     | -      | -    | -      | -    | Deleterious (0) | 34     | 5.64       |
|        | Nfasc 186c.1076G>C;p.R359P        |         |       |       |         |      |        |      | Probably damaging (0.812) |
|        | Nfasc 155c.1109G>C;p.R370P        |         |       |       |         |      |        |      | Deleterious (0.75) |
| 6      | 1:204971817–204971817            | ENST00000339876.6 | -     | -     | -      | -    | -      | -    | Tolerated (0.09) | 22.7   | 5.63       |
|        | Nfasc 186c.3230T>C;p.V1077A       |         |       |       |         |      |        |      | Possibly damaging (0.986) |

A CADD score $\geq 20$ indicates that the variant is predicted to be among the 1% most deleterious substitutions in the protein-coding parts of the human genome. A GERP++ score of close to 6 indicates a high evolutionary conservation of the NFASC sequence across species.
Figure 2 Pedigrees, Sanger sequencing, multiple-sequence alignment of NFASC and clinico-radiological natural history of patients. (A) Pedigrees of the six families carrying biallelic NFASC mutations and Sanger sequencing electropherograms confirming the mutations. (B) Facial pictures of Patients 1–3; note the facial hypomimia present in all cases, the muscle weakness and inability to hold his neck in Patient 1 carrying the p.P694T variant, and the tongue protrusion in Patients 2 and 3 carrying the frameshift mutation p.P939Ter. (C) MRIs of Patients 1–3 and 10 showing loss of cerebral white matter and atrophic changes of corpus callosum and brainstem: T2-weighted coronal MRI showing enlarged lateral ventricles in Patient 1 indicative of cortical volume loss (top left). T1-weighted sagittal MRI-sequence of Proband 2 displaying thin corpus callosum as well as cortical volume loss (top right). Axial T2-weighted sequence in Patient 3 showing progressive loss of cerebral white and grey matter (bottom left). T1-weighted sagittal MRI-sequence of Proband 10 displaying thin corpus callosum as well as cortical volume loss (bottom right). (D) In silico modelling of the 3D structure of the p.N130D and p.R359P variants. In the top left image [wild-type (WT) protein], a hydrogen bonding interaction with the side chain of glutamine 46 is visible. The residue of lysine 49 is distant from the point of mutation and forms a salt bridge with the carbonyl moiety of residue tyrosine 416. In addition, a weaker hydrophobic (cation-/C25) interaction forms between the side chains of lysine 49 and tyrosine 416 (red dashes, connecting the charged nitrogen atom with the centre of the phenyl ring). The top right image shows the different hydrogen bonding network formed in the mutant: the mutated aspartate residue forms three hydrogen bonding interactions, two involving its side chain and the side chain of lysine 49, and the third between its amino moiety and the side chain of residue glutamine 46. No interactions are visible between residues lysine 46 and tyrosine 416 that are further apart (~6 Å) and with an unsuitable geometry. In the bottom left image (wild-type protein), a strong hydrogen bonding network connects residues aspartate 352, arginine 370 and aspartate 402 positioned on three different β-strands. The absence of the arginine residue in the mutant (bottom right) impedes the formation of the hydrogen bonding network, distancing the three β-strands. (E) A schematic representation of Nfasc155 and Nfasc186 showing the position of all NFASC variants. (F) Interspecies alignment performed with Clustal Omega shows the complete conservation down to invertebrates of the amino acid residues affected by the substitutions.
is predicted to cause a non-synonymous substitution in both the two major NFASC transcripts: NM_001160331.1: c.2113C>T (p.R697F) and NM_001005388.2: c.2080G>A (p.G694T). NM_001005388.2 is the canonical NFASC transcript encoding the longest protein isoform of 1241 amino acids corresponding to Nfasc186, while NM_001160331.1 encodes the protein isoform of 1165 amino acids corresponding to Nfasc155. Sanger sequencing-based segregation analysis was performed in Family 1 confirming the variant. Through GeneMatcher and SYNAPS Study Group, we identified seven additional cases, with clinical phenotypes partially overlapping that of Family 1. WGS was carried out in Proband 2 (Fig. 2A) at Genedx, Gaithersburg, USA, by massively parallel (NextGen) sequencing on an Illumina sequencing system with 100 bp or greater paired-end reads. This revealed a homozygous single base deletion (chr1:204986105delC) predicted to cause a frameshift variant in the Nfasc155 isoform NM_001160331.1: c.2816delC (p.P939Ter) and in NFASC transcript 3 NM_015090.3: c.2771delC (p.P924Ter). The frameshift variant is expected to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. WES performed for one individual of Family 3 (Fig. 2A) detected a homozygous variant (chr1:204923488A>G), resulting in a missense change in both major transcripts: NM_001005388.2: c.388A>G (p.N124D) and NM_001160331.1: c.298A>G (p.N124D), located within a 10 Mbp stretch of homozygosity. WES in the proband of Family 4 (Fig. 2A) revealed a homozygous variant (chr1:204951136 T>C) resulting in a missense change in both NM_001005388.2: c.2458T>C (p.S820P) and NM_001160331.1: c.2491T>C (p.S831P). The index case of Family 5 (Fig. 2A) was subjected to WES as described elsewhere (Anazi et al., 2017). A homozygous missense variant in NFASC was identified in chr1:204939816G>C. This variant is predicted in both major transcripts as a non-synonymous substitution: NM_001160331.1: c.1109G>C (p.R370P) and NM_001005388.2: c.1076G>C (p.R359P) and it segregates with the disease in the family (Patients 7 and 8). Family 6 was identified from replication cohort screening, where WES carried out in Proband 9 and 10 and their parents revealed a homozygous missense variant in chr1:204971817T>C. This variant is predicted to be a non-synonymous substitution only in the NF186 transcript: NFASC (NM_001005388.2:c.3230 T>C (p.V1077A)) and it segregates with the disease in the family.

Presentation of the neurofascin disease

Table 2 summarizes the core phenotypic features of 10 individuals (aged between 3 months and 21 years), including two patients from a Saudi Arabian family (Patients 7 and 8) described previously (Anazi et al., 2017). Figure 2B and C illustrates the clinical features and MRI scans of affected individuals from each family. In all patients, psychomotor development was severely delayed (except Patients 5 and 6) in all domains. Affected individuals did not communicate, and none achieved purposeful hand movements or independent ambulation. Hypotonia was present from neonatal age in all cases. Impaired social interaction and only brief and occasional visual contact were noticed in all affected individuals by the first year of age. Several patients developed restricted patterns of interests and repetitive behaviours and frequently exhibited hand or head stereotypies. Moderate to severe intellectual disability was documented in all cases. None of the affected individuals attained intelligible speech. Because of muscle weakness and absent reflexes, individuals from Families 1, 2, 4 and 6 underwent detailed neurophysiological investigations as part of their diagnostic work-up and these showed a severe reduction in peripheral nerve conduction velocities in all cases. Patients from Families 1 and 2 exhibited the most profound phenotype with severe demyelinating and axonal neuropathy at neurophysiological investigations. Non-specific EEG abnormalities including slow background activities were observed in several families although affected individuals had no history of seizures. Given that NFASC is expressed in various brain regions, with the highest transcript level in the white matter region (Supplementary Fig. 7), MRI studies of Patients 1–3, 7, 9 and 10 showed loss of cerebral white matter, which was more severe in some affected individuals (Patients 1–3) and also associated with atrophic changes mainly involving the corpus callosum and the brainstem (Fig. 2C). T2-weighted coronal MRI showing enlarged lateral ventricles in Patient 1 indicative of cortical volume loss (Fig. 2C). Interestingly, similar MRI patterns were also observed in CASPR1-deficient patients with brainstem and corpus callosum atrophy (Hengel et al., 2017). Previously, cerebellar atrophy has been directly associated with loss of NFASC in both Purkinje and basket neurons causing abnormal basket axon collateral branching and targeting to the axon initial segment, leading to extensive penicu disorganization, Purkinje neuron degeneration and severe ataxia (Buttermore et al., 2012). Because of their severe muscle weakness, the majority of affected individuals had non-expressive/hypomimic face, and several craniofacial dysmorphisms including bi-temporal narrowing, high and wide nasal bridge, micrognathia, glossoptosis and highly arched palate (Fig. 2B). The two American children had more severe phenotype and also developed profound sensorineural hearing loss, feeding difficulties requiring gastrostomy and respiratory difficulties. The younger of the two Saudi Arabian children exhibited skeletal chest deformities and generalized hypertonia (mainly affecting upper limbs) and died at the age of 4 months, presumably due to aspiration defects. The two French children identified from replication cohort screening have an older age of onset compared to the rest of the patients, and the fact that the Nfasc155 transcript is intact while the missense variant is only present in Nfasc186 could imply a different mode of disease evolution.
### Table 2 Genetic, clinical and neurophysiology details of patients with NFASC variants

| Patient | Gender | Origin      | Current age | Variant                  | Age at onset of initial symptoms | Intellectual disability | Speech impairment | Neurological examination | Sensory NCS | Motor NCS | EMG | MRI |
|---------|--------|-------------|-------------|--------------------------|---------------------------------|--------------------------|-------------------|--------------------------|-------------|-----------|-----|-----|
| 1       | Male   | Moroccan    | 4 years     | c.2090C > A; p.P694T     | Neonatal hypotonia              | +                        | +                 | Weakness, absent reflex, abnormal sensation, no walk | Reduced CV, normal Amp | NT        | NT  | NT  |
| 2       | Male   | American    | 1 year and 6 months | c.2816delC; p.P939Ter  | Neonatal hypotonia              | +                        | +                 | Weakness, no walk          | Reduced CV, normal Amp | NT        | NT  | NT  |
| 3       | Female | American    | 10 years    | c.2816delC; p.P939Ter  | Neonatal hypotonia              | +                        | +                 | Weakness, no walk          | Reduced CV, normal Amp | NT        | NT  | NT  |
| 4       | Male   | Arab Iraqi  | 3 years     | c.2458T > C; p.S820P     | Hypotonia during the first 6 months of life | +                        | +                 | Weakness, no walk          | Reduced CV, normal Amp | NT        | NT  | NT  |
| 5       | Male   | Israeli     | 12 years    | c.2458T > C; p.S820P     | Hypotonia during the first 6 months of life | +                        | +                 | Weakness, no walk          | Reduced CV, normal Amp | NT        | NT  | NT  |
| 6       | Male   | Israeli     | 16 years    | c.1076G > C; p.R359P     | Hypotonia during the first 3 months of life | +                        | +                 | Weakness, no walk          | Reduced CV, normal Amp | NT        | NT  | NT  |
| 7       | Male   | Saudi Arabian | 2 years and 6 months | c.388A > G; p.N130D    | Hypotonia during the first 2 months of life | +                        | +                 | Weakness, no walk          | Reduced CV, normal Amp | NT        | NT  | NT  |
| 8       | Male   | Saudi Arabian | 4 months (at time of death) | c.1076G > C; p.R359P | Hypotonia during the first 3 months of life | +                        | +                 | Weakness, no walk          | Reduced CV, normal Amp | NT        | NT  | NT  |
| 9       | Female | Algerian    | 21 years    | c.3230T > C; p.V1077A   | Neonatal hypotonia              | +                        | +                 | Weakness, no walk          | Reduced CV, normal Amp | NT        | NT  | NT  |
| 10      | Female | Algerian    | 16 years    | c.3230T > C; p.V1077A   | Neonatal hypotonia              | +                        | +                 | Weakness, no walk          | Reduced CV, normal Amp | NT        | NT  | NT  |
|         | Female | Italian     | 2 years     | c.2491C > T; p.V1122E    | Spastic limb hypotonia          | +                        | +                 | Weakness, no walk          | Reduced CV, normal Amp | NT        | NT  | NT  |
|         | Female | Algerian    | 16 years    | c.1076G > C; p.R359P     | Hypotonia during the first 2 months of life | +                        | +                 | Weakness, no walk          | Reduced CV, normal Amp | NT        | NT  | NT  |
|         | Female | Italian     | 1 year      | c.3365T > A; p.V1122E    | Spastic limb hypotonia          | +                        | +                 | Weakness, no walk          | Reduced CV, normal Amp | NT        | NT  | NT  |

---

- = absent; + = present; Amp = amplitude; CV = conduction velocity/velocities; NA = not applicable; NCS = nerve conduction studies; NT = not tested; PSW = positive sharp waves; SSR = sympathetic skin response.
Molecular modelling

To examine if these disease-associated variants affect NFASC structure and paranodal junction stability, 500 ns molecular dynamics simulations were performed using mutant ectodomain models based on the humanized wild-type as a template. Rearrangements on the variant sites showed that even though p.R370P gives no significant fluctuations in terms of protein conformation and movement, a weaker hydrophobic bond in residues 49 and 416 of the p.N130D protein can make its conformation less regular (Fig. 2). While the wild-type and p.R370P settle in a stationary state, p.N130D results in a slightly compressed mutant. This is evident in their backbone root mean squared deviation (RMSD) (Supplementary Fig. 4), which measures the divergence of the mutant protein structure from its initial structure over the course of the simulation and radius of gyration (Rg), which gives an indication on the change in size of the protein. In all cases, the most mobile portion of the chain is residue 237 (corresponding to residue 248 in the transcript containing the p.R370P variant) as seen (Supplementary Fig. 4) in their root mean squared fluctuation (RMSF), which indicated how much each residue diverges from its initial position. This arginine residue is exposed to the aqueous solvent and part of a larger loop, probably flexible and crucial to protein dynamics. The RMSF further indicates that in all cases on average the overall mobility of the backbone is not particularly affected by variants.

Surface expression and protein levels of NFASC variants

To determine the impact of genetic variants on NFASC function, mutations were introduced in plasmids encoding Myc-tagged human Nfasc155 or Nfasc186. In the case of the p.P939Ter variant, the Myc-tag was inserted before the premature stop codon in the aberrant C-terminal extension. HEK cells were then transfected with these constructs and the neurofascin cell surface expression was monitored by immunocytochemistry (Fig. 3 and Supplementary Fig. 1). To detect surface expression of NFASC isoforms, living transfected cells were incubated with antibodies to Nfasc155 or Nfasc186 for 20 min, then cells were fixed, permeabilized and immunostained for Myc. Wild-type Nfasc155 (Fig. 3A) and Nfasc186 (Supplementary Fig. 1 and 2) are readily expressed at the cell surface and a complete co-localization is observed between the cell surface proteins and the Myc-labelled proteins after permeabilization. Most of the NFASC variants did not seem to affect the surface expression of Nfasc155 or Nfasc186, and a clear co-localization could be detected between surface-labelled and Myc-labelled proteins (Fig. 3B–E and Supplementary Fig. 1). Only the p.P939Ter variant strikingly affected the expression of Nfasc155. This mutant protein was not detectable at the cell surface, or after Myc labelling. To confirm this observation, cells were co-transfected with GFP then fixed and stained for Myc. When cells were co-transfected with wild-type Nfasc155, all GFP-labelled cells also co-expressed Myc-tagged Nfasc155 at the cell surface (Fig. 3F). By contrast, no cell surface immunostaining was detected in cells co-transfected with p.P939Ter (Fig. 3G). This suggested that the variant abolished Nfasc155 expression.

To confirm this observation further, we examined the protein levels of Nfasc155 variants by western immunoblotting (Fig. 3H). The protein levels of p.P705T, p.S807P and p.P939Ter mutants were found importantly decreased compared to wild-type Nfasc155 (Fig. 3I). Particularly, p.P939Ter was not detectable on immunoblots even at lower molecular weight. By contrast, the p.N124D and p.R370P variants had no significant effect on Nfasc155 protein levels. Because p.P939Ter is a frameshift variant inducing a premature stop codon before the transmembrane domain of Nfasc155, we suspected that this protein may be released in the culture medium. We thus harvested the cell culture medium and immunoblotted the released fraction for Myc antibodies. No signal was detected in the released fraction even after acetone precipitation and concentration of the sample (data not shown), indicating that the p.P939Ter variant abolishes Nfasc155 expression.

Nfasc155 variants inhibit the interaction with CNTN1/CASPR1

Nfasc155 is known to interact with CASPR1 and CNTN1 at the paranodal regions of myelinated axons, and deletion of CNTN1 or CASPR1 leads to important conduction slowing in myelin-deficient mice (Sherman et al., 2005). Because the affected patients presented demyelinating features, we suspected that Nfasc155 variants may alter its interaction with these axonal partners. To test this hypothesis, N2A cells were co-transfected with CNTN1, CASPR1, and GFP, then incubated for 2 h with cells co-expressing Nfasc155 and tandem tomato (Fig. 3). The number of cell aggregates was then quantified. As negative control, N2A cells expressing Nfasc155 were incubated with cells expressing GFP alone (Fig. 3). In keeping with a previous report (Labasque et al., 2014), we found that N2A cells expressing CNTN1/CASPR1 readily interact and form aggregates with Nfasc155-expressing cells (Fig. 3J–O). By contrast, only a minimal interaction was observed between Nfasc155-expressing cells and GFP alone (Fig. 3P). Both p.P705T and p.P939Ter variants abolished the interaction between Nfasc155 and CNTN1/CASPR1, indicating that these variants impact Nfasc155 function (Fig. 3L, O and P). To determine whether the genetic variants may also affect the surface expression of Nfasc186 or the interaction of Nfasc186 with gliomedin, we tested these on a western blot and also tested the binding of gliomedin-Fc on Nfasc186-transfected cells. The blot showed p.N130D had a higher expression level, while the other mutants had a normal expression level compared to wild-type.
Figure 3 Membrane targeting of Nfasc155 variants. The homozygous Nfasc155 variants associated with a severe pathology diminish Nfasc155 protein level. The variants p.P705T and p.P939Ter inhibit the association of CASPR1/CNTN1 with Nfasc155. (A–E) HEK cells were
(continued)
Nfasc186 (Supplementary Fig. 2). In addition, no alterations on gliomedin binding were observed on any of the Nfasc186 variants (Supplementary Fig. 1).

Immunofluorescence staining analysis

In protein gene product 9.5/collagen IV (PGP/COLIV) double-stained sections of both arm and leg samples from Patient 1 (Fig. 4), cutaneous innervation appeared quite preserved (Fig. 4B and B1 compared to A). In particular, epidermal nerve fibres as well as sudomotor and pilomotor nerve fibres appeared normally represented and regularly distributed. Conversely, a severe loss of myelinated fibres was observed around the hair follicle as evidenced by the simplification of the so called ‘palisade-like’ endings originating from the few remaining myelinated fibres (Fig. 4D and D1 compared to C). Myelin staining appeared very weak with some bright spots along the nerve course (Fig. 4D and D1). No further myelinated fibres were observed in MBP/PGP double-stained sections. However, small nerve fascicles were recognized in the deep dermis in sections double-stained with Nfasc186/MBP (Fig. 4F and F1 compared to E), panNeurofascin/MBP (Fig. 4H and H1 compared to G) and CASPR1/MBP (Fig. 4J and J1 compared to I). Also, in these fascicles the MBP-immunoreactivity appeared very weak or absent and again bright spots were present along the nerve course. Nfasc186 immunoreactivity was normally expressed in the nodal region along few profiles of nerve fibres, as well as panNeurofascin and CASPR1 immunoreactivity at the paranodes. In general, we observed a severe loss of myelinated fibres with a preservation of the unmyelinated ones. The abnormal immunoreactivity to MBP antibody suggests a severe myelin involvement leading to probable nerve degeneration. In contrast, the expression of Nfasc186 in the nodal regions and of panNeurofascin and CASPR1 in the paranodal regions appeared normal, although limited to the few remaining fibres. The observation of few paranodes stained with CASPR1 as well as with panNeurofascin suggests that the absence of Nfasc155 is partial in Patient 1.

In PGP/CollIV double-stained sections from Patient 3 (Fig. 5), cutaneous innervation appeared quite preserved in the epidermis (Fig. 5A and A1) and around sweat glands and other autonomic annexes (Fig. 5C) in all three examined sites. Observing MBP/PGP double-stained sections from distal leg, it was evident a severe loss of myelinated fibres surrounding the hair follicle with few segments showing severe myelin abnormalities (Fig. 5B, B1). In MBP/PGP double stained skin sections from the proximal site (thigh), myelinated fibres appeared more preserved with several myelinated segments visible around a hair follicle (Fig. 5C and C1). Similarly, we could sample a definitely larger amount of myelinated fibres from the fingertip (Fig. 5D and D1) compared to the other two sites, although there was an evident loss of mechanoreceptors and myelinated fibres compared to a control case (Fig. 5E and E1). At higher magnification, we observed abnormalities of myelin sheet and enlargement of the nodal gap (Supplementary Fig. 3A). In Nfasc186/MBP images, we observed a normal expression of neurofilament staining in the node (Supplementary Fig. 3B). The nodal structure appeared identical by visualizing the node with the anti-panNeurofascin or the anti-Nfasc186 antibodies (Supplementary Fig. 3C). CASPR1 immunoreactivity was completely absent in the paranodal regions (Supplementary Fig. 3D). Additionally, an apparently normal distribution of voltage-gated sodium (Na\textsubscript{v}) channels appeared in MBP/Na\textsubscript{v} double-staining images in several nodes that appeared larger, however less compacted than in the control skin (Supplementary Fig. 3F). Moreover, a granular distribution of Na\textsubscript{v} was evident along the axonal profiles of large fibres devoid of myelin (arrows in Supplementary Fig. 3E) that suggested a Na\textsubscript{v} remodelling.

Figure 3 Continued

transfected with Myc-tagged Nfasc155 variants and surface Nfasc155 was monitored by incubating the live cells with anti-Nfasc155 IgG (red) prior to fixation and permeabilization. Nfasc155 was then revealed using an anti-Myc antibody (green). Wild-type Nfasc155, but also the variants pN124D, pR370P, pP705T and pS831P were readily targeted at the cell surface, and did not show signs of intracellular retention. (F–G) HEK cells were co-transfected with GFP (green) and either wild-type Nfasc155 or pP939Ter variant, then cells were immunostained for Myc (red). In contrast to wild-type Nfasc155, pP939Ter was not detectable, indicating that this mutation strongly affects Nfasc155 expression. Nuclei are stained DAPI (blue). Scale bar = 10 μm. (H) Western blot analysis of HEK cells transfected with Nfasc155 variants and revealed with anti-Myc antibodies or anti-a-tubulin antibodies as loading control. (I) Protein expression levels were analysed by normalizing the signals to the corresponding α-tubulin signal, then to wild-type Nfasc155 in four independent experiments. The expression levels of pP705T, pS831P and pP939Ter variants were significantly decreased compared to wild-type Nfasc155 (Mann-Whitney test). *p < 0.01; **p < 0.005; ***p < 0.001; by unpaired two-tailed Student's t-tests for two samples of equal variance and by one-way ANOVA followed by Bonferroni’s post hoc tests. Bars represent mean and SEM. Molecular weight markers are shown on the left (in kDa). N.S. = not significant. (J–O) N2A cells were transfected with GFP (green) in combination with CNTN1 and CASPR1 and were incubated for 2 h with cells transfected with tandem tomato (magenta) and wild-type Nfasc155 (J), pP705T (M) or pP939Ter (O). As negative control, N2A cells transfected with Nfasc155 (magenta) were incubated with cells transfected with GFP. (P) The numbers of green and magenta cell aggregates (dashed line circles in J–O) per visualization field were quantified in each condition (n = 4 experiments for each condition). pR370P, pP705T, pS831P and pP939Ter mutations significantly decreased aggregate formation. ***p < 0.001 by unpaired two-tailed Student's t-tests and by one-way ANOVA followed by Bonferroni's post hoc tests. Bars represent mean and SEM. Scale bar = 20 μm.
Figure 4 Severe involvement of peripheral myelinated fibres and partial disruption of Nfasc155 at the paranode in Patient 1. Confocal images of cutaneous innervation from hairy skin (leg and arm) of the patient compared to a control showing well preserved unmyelinated fibres in the epidermis and dermis (B and B1 compared to A), severe loss of myelinated fibres around a hair follicle and the few remaining ones presenting a very weak MBP (red) immunoreactivity (D, D1 arrowheads compared to C), in a nerve bundle with few remaining myelinated fibres presenting a very faint staining with MBP antibody presence of nodes marked with Nfasc186 (green) (F and F1 compared to E), paranodes marked with panNeurofascin (green) (H, H1 arrowheads compared to G) and paranodes marked with CASPR (green) (J and J1 arrowheads compared to I). Scale bar = 100 μm in A, B, B1; 50 μm in C, D, D1; 30 μm in F–J1.
after demyelinating phenomena. Those data indicate that the frameshift variant in Patient 3, which induces a complete lack of Nfasc155 expression, does not provoke a complete disruption of the node. There was, however, a severe alteration of the paranode as showed by the complete absence of the CASPR1, the physiological ligand of Nfasc155, and a severe effect on myelination and/or maintenance of myelin and survival of large fibres, which appears to be length-dependent. Interestingly, small fibres, both somatic and autonomic appeared less affected by the variant in both patients.

**NFASC cell-specific expression and co-expression analysis**

We first explored the expression of NFASC in the central and peripheral nervous system using publicly available cell-specific transcriptomic data (Zhang et al., 2016; Zeisel et al., 2018). In keeping with the known function of NFASC, RNA sequencing of purified cell types derived from human cortex demonstrated that NFASC was most highly expressed in oligodendrocytes though there was also evidence of expression in neurons and, to a lesser extent, astrocytes and endothelial cells (Supplementary Fig. 6). We also found that NFASC expression was highest in newly formed oligodendrocytes rather than myelin-forming or mature oligodendrocytes. Next, we investigated the function of NFASC using gene co-expression analysis to construct networks for all 13 human brain regions sampled by the Genotype Tissue Expression Consortium (Supplementary Table 2) (Human Genomics, 2015). In the anterior cingulate cortex, NFASC was located with high confidence (module membership = 0.74) within a co-expression module, which is enriched for genes involved in synaptic transmission (GO:0099536, chemical synaptic transmission FDR-corrected $P$-value = $6.68 \times 10^{-10}$) and expressed specifically in neurons (neuron module in cortex, FDR-corrected $P$-value = $6.0 \times 10^{-7}$). Furthermore, this module was enriched for genes known to be associated with monogenic forms of intellectual disability (FDR-corrected $P$-value $2.12 \times 10^{-3}$, Supplementary Fig. 5).

**Discussion**

Homozygous variants in NFASC lead to a neurodevelopmental disorder that includes—in some families—a chronic demyelinating neuropathy. Radiological features in some NFASC individuals included central white matter loss and atrophy of the corpus callosum and the brainstem (Fig. 2C). As part of their phenotype, several affected individuals also exhibited features of central demyelination and clinical and neurophysiological evidences of chronic peripheral demyelinating neuropathy associated with severe reduction in nerve conduction velocities and prolonged motor latencies (Table 2 and Supplementary Table 1). Interestingly, these patients have a similar phenotype to patients with CNTNAP1/CASPR1 mutations; however, without any epilepsy, which has been reported in CASPR1-mutated patients. It is possible that a different...
role is played by CASPR1 and NFASC in neuron excitability at CNS level (Laquerriere et al., 2014; Hengel et al., 2017).

Immunoglobulin G subclass 4 (IgG4) antibodies to Nfasc155 and Nfasc186 have been identified in 3–18% of patients with chronic inflammatory demyelinating polyradiculoneuropathy (Querol et al., 2014; Ogata et al., 2015; Delmont et al., 2017). Nfasc155 IgG4 antibodies are associated with specific clinical features including an early onset of the CIDP disease, a distal predominant pattern of weakness, and the presence of sensory ataxia and tremor. A cerebellar origin of the tremor has been hypothesized in some cases (Devaux, 2014; Querol et al., 2014; Ogata et al., 2015). Also, and most importantly to the present study, up to 8% of CIDP patients with IgG4 Nfasc155 showed evidence of CNS demyelination (Devaux et al., 2016) and anti-Nfasc155 antibodies were identified at high frequency in Japanese patients with combined central and peripheral demyelination (Kawamura et al., 2013), although this was not replicated in the Caucasian population (Cortese et al., 2016).

The majority of NFASC mutated individuals identified in this study were found with homozygous missense variants affecting highly conserved residues within the Ig-like domains or in the fibronectin type III domains of the neurofascin protein (Fig. 2E). One family (Family 2) was identified with a homozygous frameshift deletion predicted to result in a premature truncation of the protein. Among our patients, affected individuals from Family 2 carrying the p.P939Ter frameshift deletion exhibited the more severe phenotype with marked neurodevelopmental impairment and profound muscle weakness associated with severe reduction of conduction velocities on neurophysiological investigations. Given the history of consanguineous marriages in these families, other recessive variants may also have contributed to the clinical phenotype, as in Proband 8 from Family 5 who died prematurely, presumably because of aspiration due to respiratory difficulties.

The results from our functional analyses indicate abnormal Nfasc155 interaction with CNTN1 and CASPR1 as an important disease mechanism in the NFASC-related genetic disease. In addition, loss of Nfasc155 surface expression may also be implicated in the phenotype observed in the affected individuals. Immunofluorescence studies on Patients 1 and 3 detected a severe loss of myelinated fibres with a preservation of the unmyelinated ones, and while the expression of Nfasc186 in the nodal regions appeared normal in both patients, the absence of Nfasc155 in the paranodal region was only partial in Patient 1. Western blot showed that the protein levels of several Nfasc155 mutants including p.P705T and p.P939Ter were importantly decreased compared to wild-type Nfasc155. These biochemical findings support the morphological findings and indicate that there may be an incomplete derangement of the paranodal region in some patients due to a reduction of glial Nfasc155. This could explain the relatively milder phenotype of Patients 6 and 7 as well as that of the recently described patient with a similar neurodevelopmental syndrome (Smigiel et al., 2018).

Of interest, in cell-specific in silico studies, NFASC is mostly expressed in newly formed oligodendrocytes, and found to be enriched for genes associated with monogenic forms of intellectual disability. Given recent evidence that the generation of new myelin segments is an important form of plasticity that can be used to modify the properties of circuits in the CNS (McKenzie et al., 2014; Xiao et al., 2016), these observations may be significant and provide some explanation for the neurodevelopmental features of individuals carrying biallelic NFASC variants. We could further speculate that in at least some brain regions NFASC may play an important role in synaptic transmission and that this potentially might explain how biallelic variants in the gene result in central neurological features.

Interestingly, homozygous NFASC-null mice are born with a normal appearance but die suddenly 7 days after birth when the postnatal transition to saltatory conduction is occurring in the CNS and PNS. Over-expression of either of the two neuronal isoforms (Nfasc186 or Nfasc140) helps them survive into adulthood but mice are ataxic, presumably because they do not have intact paranodal axoglial junctions in their myelinated nerves (Sherman et al., 2005).

Recently, a homozygous splice-site variant in NFASC was identified in an individual with neurodevelopmental impairment, hypotonia and areflexia (Farwell Hagman et al., 2017). Another family was found within a large genetic study carrying a homozygous NFASC variant associated spinal muscular atrophy (Smigiel et al., 2018) and a homoyogous missense mutation leads to significant loss of NFASC protein in induced pluripotent stem cell-derived neurons from affected subjects (Monfrini et al., 2019).

Despite these reports, the implication of NFASC mutations in the development of human diseases remains to be fully elucidated and warrants further investigations on a larger scale. Our results strongly establish the association of biallelic NFASC variants in the complex central and peripheral nervous system involvement presented by the 10 affected individuals described in this study. The notion of a genetic NFASC disease further delineates an emerging spectrum of human neurological disorders caused by variants in cell adhesion and ankyrin-binding genes involved in neurite extension, axonal guidance, synaptogenesis, myelination and neuron-glial cell interactions.

Acknowledgements

We gratefully acknowledge the families for their enthusiastic collaboration in this study.

Funding

We greatly appreciate the financial support provided by The Wellcome Trust and strategic award (Synaptopathies).
funding (WT093205 MA and WT104033AIA). Grant funding was provided by the MRC (MR/S01165X/1, MR/S005021/1, G0601943), The National Institute for Health Research University College London Hospitals Biomedical Research Centre, Rosetree Trust, Ataxia UK, MSA Trust, Brain Research UK, Sparks GOSH Charity, Muscular Dystrophy UK (MDUK), Muscular Dystrophy Association (MDA USA). We also acknowledge the CINECA Awards N. HP10CRVL.7F, 2017, for the availability of high-performance computing resources and support, as well as the funding from Radboudumc and RIMLS Nijmegen (Hypatia tenure track fellowship), the “Deutsche Forschungsgemeinschaft” (DFG CRC1140 KIDGEM) and the European Research Council (ERC StG TREATCila, grant No 716344). The biochemistry work was supported by the Association Française contre les Myopathies (grant#21532; J.D.). S.W. is supported by the Ministry of Science, Research and the Arts of Baden-Württemberg and the European Social Fund (ESF) of Baden-Württemberg (31–7635 41/67/1).

Competing interests

L.B.H. and E.T. are employees of GeneDx, Inc., a wholly owned subsidiary of OPKO Health, Inc.

Supplementary material

Supplementary material is available at Brain online.

Appendix 1

SYNAPS Study Group

Full details are available in the Supplementary material.

Stanislav Groppa, Blagovesta Marinova Karashova, Wolfgang Nachbauer, Sylvia Boesch, Larissa Arning, Dagmar Timmann, Brü Cormand, Belen Pérez-Dueñas, Jatinder S. Goraya, Tipu Sultan, Jun Mine, Daniela Avdiujeva, Hadil Kathom, Radka Tincheva, Selina Banu, Mercedes Pineda-Goraya, Tipu Sultan, Jun Mine, Daniela Avdiujeva, Hadil Kathom, Radka Tincheva, Selina Banu, Mercedes Pineda-Goraya, Stanislav Groppa, Blagovesta Marinova Karashova, Wolfgang Nachbauer, Sylvia Boesch, Larissa Arning, Dagmar Timmann, Brü Cormand, Belen Pérez-Dueñas, Jatinder S. Goraya, Tipu Sultan, Jun Mine, Daniela Avdiujeva, Hadil Kathom, Radka Tincheva, Selina Banu, Mercedes Pineda-Goraya.

References

Anazi S, Maddirevula S, Faqeh E, Alsedairi H, Alzahrani F, Shamseldin HE, et al. Clinical genomics expands the morbid genome of intellectual disability and offers a high diagnostic yield. Mol Psychiatry 2017; 22: 615–24.

Arancibia-Carcaro IL, Atwell D. The node of Ranvier in CNS pathology. Acta Neuropathol 2014; 128: 161–75.

Bussi G, Donadio D, Parrinello M. Canonical sampling through velocity rescaling. J Chem Phys 2007; 126: 014101.

Buttermere ED, Piochon C, Wallace ML, Philpot BD, Hansel C, Bhat MA. Pinceau organization in the cerebellum requires distinct functions of neurofascin in Purkinje and basket neurons during postnatal development. J Neurosci 2012; 32: 4724–42.

Carithers LJ, Ardlie K, Barcus M, Brantoon PA, Britton A, Buia SA, et al. A novel approach to high-quality postmortem tissue procurement: the GTEx project. Biopreserv Biobank 2015; 13: 311–9.

Chemin J, Siquier-Pernet K, Nicouleau M, Barcia G, Ahmad A, Medina-Canó D, et al. De novo mutation screening in childhood-onset cerebellar atrophy identifies gain-of-function mutations in the CACNA1G calcium channel gene. Brain 2018; 141: 1998–2013.

Cortese A, Devaux JJ, Zardini E, Manso C, Taieb G, Carra Dalliere C, et al. Neurofascin-155 as a putative antigen in combined central and peripheral demyelination. Neurol Neuroimmunol Neuroinflamm 2016; 3: e238.

Delmont E, Manso C, Querol L, Cortese A, Berardinelli A, Lozza A, et al. Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain 2017; 140: 1851–8.

Devaux JJ. Antibodies to gliomedin cause peripheral demyelinating neuropathy and the dismantling of the nodes of Ranvier. Am J Pathol 2012; 181: 1402–13.

Devaux JJ. [New insights on the organization of the nodes of Ranvier]. Rev Neurol (Paris) 2014; 170: 819–24.

Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, Belghazi M, et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 2016; 86: 800–7.

Fabregat A, Korninger F, Viteri G, Sidiropoulos K, Marin-Garcia P, Ping P, et al. Reactome graph database: efficient access to complex pathway data. PLoS Comput Biol 2018; 14: e1005968.

Farwell Hagman KD, Shinde DN, Mroskij M, Smith E, Radtke K, Rahmimaz L, et al. Candidate-gene criteria for clinical reporting: diagnostic exome sequencing identifies altered candidate genes among 3% of patients with undiagnosed diseases. Genet Med 2017; 19: 224–35.

Ghosh A, Sherman DL, Brophy PJ. The Axonal Cytoskeleton and Neuropathy. J Neurosci 2012; 32: 11007–15.

Hengel H, Magee J, Arancibia-Carcaro IL, Attwell D. The node of Ranvier in CNS pathology. Acta Neuropathol 2014; 128: 161–75.

Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118–27.

Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M, et al. Reactome graph database: efficient access to complex pathway data. PLoS Comput Biol 2018; 14: e1005968.

Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M, et al. Reactome graph database: efficient access to complex pathway data. PLoS Comput Biol 2018; 14: e1005968.

Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M, et al. Reactome graph database: efficient access to complex pathway data. PLoS Comput Biol 2018; 14: e1005968.

Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M, et al. Reactome graph database: efficient access to complex pathway data. PLoS Comput Biol 2018; 14: e1005968.

Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M, et al. Reactome graph database: efficient access to complex pathway data. PLoS Comput Biol 2018; 14: e1005968.

Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M, et al. Reactome graph database: efficient access to complex pathway data. PLoS Comput Biol 2018; 14: e1005968.

Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M, et al. Reactome graph database: efficient access to complex pathway data. PLoS Comput Biol 2018; 14: e1005968.

Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M, et al. Reactome graph database: efficient access to complex pathway data. PLoS Comput Biol 2018; 14: e1005968.
Labasque M, Hivert B, Nogales-Gadea G, Querol L, Illa I, Faivre-Sarrailh C. Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. J Biol Chem 2014; 289: 7907–18.

Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform 2008; 9: 559.

Laquerriere A, Maluenda J, Camus A, Fontenas L, Dieterich K, Nolent F, et al. Mutations in CNTNAP1 and ADCY6 are responsible for severe arthrogryposis multiplex congenita with axoglial defects. Hum Mol Genet 2014; 23: 2279–89.

Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet 2007; 3: 1724–35.

Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 2010; 78: 1950–8.

Maluenda J, Manso C, Quevarec L, Vivanti A, Marguet F, Gonzales M, et al. Mutations in GLDN, encoding gliomedin, a critical component of the nodes of ranvier, are responsible for lethal arthrogryposis. Am J Hum Genet 2016; 99: 928–33.

McKenzie IA, Ohayon D, Li H, De Faria JP, Emery B, Tohyama K, et al. Motor skill learning requires active central myelination. Science 2014; 346: 318–22.

Mencacci NE, Kamsteeg EJ, Nakashima K, R’Bibo L, Lynch DS, Balint B, et al. De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal Lesions. Am J Hum Genet 2016; 98: 763–71.

Monfrini E, Straniero L, Bonato S, Monzio Compagnoni G, Bordoni A, Dilena R, et al. Neurofascin (NFASC) gene mutation causes autosomal recessive ataxia with demyelinating neuropathy. Parkinsonism Relat Disord 2019; 63: 66–72.

Ogata H, Yamasaki R, Hiwatashi A, Oka N, Kawamura N, Matsuse D, et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol 2015; 2: 960–71.

Pronk S, Pall S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 2013; 29: 845–54.

Querol L, Nogales-Gadea G, Rojas-Garcia R, Diaz-Manera J, Pardo J, Ortega-Moreno A, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 2014; 82: 879–86.

Querol L, Siles AM, Alba-Rovira R, Jauregui A, Devaux J, Faivre-Sarrailh C, et al. Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Sci Rep 2017; 7: 14411.

Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, et al. Clinical application of whole-exome sequencing across clinical indications. Genet Med 2016; 18: 696–704.

Sherman DL, Tait S, Melrose S, Johnson R, Zonta B, Court FA, et al. Neurofascins are required to establish axonal domains for saltatory conduction. Neuron 2005; 48: 737–42.

Smigiel R, Sherman DL, Rydzanicz M, Walszak A, Mikolajkow D, Krolak-Olejnik B, et al. Homozygous mutation in the Neurofascin gene affecting the glial isoform of Neurofascin causes severe neurodevelopment disorder with hypotonia, amimia and areflexia. Hum Mol Genet 2018; 27: 3669–74.

Taylor AM, Shi Q, Bhat MA. Simultaneous ablation of neuronal neurofascin and ankyrin g in young and adult mice reveals age-dependent increase in nodal stability in myelinated axons and differential effects on the lifespan. eNeuro 2018; 5: ENEURO.0138–18.2018.

Vallat JM, Mathis S, Magy L, Bounolleau P, Skarzynski M, Heitzmann A, et al. Subacute nodopathy with conduction blocks and anti-neurofascin 140/186 antibodies: an ultrastructural study. Brain 2018; 141: e65.

Xiao L, Ohayon D, McKenzie IA, Sinclair-Wilson A, Wright JL, Fudge AD, et al. Rapid production of new oligodendrocytes is required in the earliest stages of motor-skill learning. Nature Neurosci 2016; 19: 1210.

Zeisel A, Hochgener H, Lonnerberg P, Johnsson A, Memic F, van der Zwan J, et al. Molecular Architecture of the Mouse Nervous System. Cell 2018; 174: 999–1014.e22.

Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 2016; 89: 37–53.